Alnylam Pharmaceuticals and Tenaya Therapeutics have entered into a research collaboration that will allow Tenaya to validate up to 15 novel genetic targets for cardiovascular disease while Alnylam will take responsibility for subsequent development and commercialization. The agreement provides Tenaya with an upfront payment of up to $10 million and a two‑year validation term, and it gives Alnylam the right to make milestone payments totaling up to $1.13 billion if the partnership leads to approved therapeutics.
The partnership expands Alnylam’s RNAi platform into a broader cardiovascular portfolio. Alnylam already markets ATTR amyloidosis therapies such as Amvuttra for transthyretin‑related cardiomyopathy, and the new collaboration will enable the company to pursue additional heart‑disease indications that could generate new revenue streams and reinforce its position as a leader in RNA interference therapeutics.
Tenaya brings expertise in identifying and validating disease‑causing genes. The company’s pipeline includes clinical‑stage candidates for hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy, and the deal’s upfront and milestone payments extend Tenaya’s financial runway into the second half of 2026. The two‑year validation period gives Tenaya time to confirm the therapeutic potential of the selected targets before Alnylam assumes full development responsibility.
Faraz Ali, CEO of Tenaya Therapeutics, said: “This multi‑target collaboration underscores Tenaya's commitment to rigorous science and capitalizes on the proprietary capabilities that have contributed to the discovery and development of Tenaya's pipeline of candidates for cardiovascular conditions. By combining our modality agnostic target identification and validation capabilities with Alnylam's leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease.”
The market reaction to the announcement was positive, driven by the substantial financial terms and the strategic fit between the two companies. Investors viewed the deal as a validation of Tenaya’s target‑identification platform and a signal that Alnylam is actively expanding its cardiovascular pipeline beyond its existing ATTR amyloidosis franchise.
The collaboration positions both companies to address unmet needs in heart disease. For Alnylam, it opens a new therapeutic area that could complement its existing RNAi portfolio and generate additional revenue. For Tenaya, the partnership provides critical funding and a clear path to commercialization, potentially accelerating the development of its cardiovascular candidates and enhancing its long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.